Inhalable Drugs Market Size, Share, and Growth Analysis

Inhalable Drugs Market By Product(Aerosol, Dry Powder Formulation, Spray, Application), By Regional(North America, U.S, Canada, Europe) - Industry Forecast 2025-2032

Report ID: UCMIG35I2239 | Region: Global | Published Date: Upcoming |
Pages: 165 |Tables: 0 |Figures: 0

Format - word format excel data power point presentation

Inhalable Drugs Market Insights

Market Overview:

The global inhalable drugs market achieved a valuation of USD 25.0 billion in 2018 and is projected to experience a notable compound annual growth rate (CAGR) of 6.3% throughout the forecast period. This upward trajectory can be primarily attributed to the escalating prevalence of respiratory conditions, notably Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis. The increasing burden of these ailments is anticipated to serve as a substantial driver propelling market expansion. For instance, in the U.S. alone, the Centers for Disease Control and Prevention (CDC) reported that more than 25 million individuals were afflicted by asthma in 2017, accounting for approximately 7.7% of the adult population and 8.4% of children. As these respiratory conditions continue to impact a significant portion of the population, the demand for inhalable drugs is expected to surge, thereby contributing to the market's sustained growth.

Inhalable Drugs Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Inhalable Drugs Market is segmented by Product, Regional. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Inhalable Drugs Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Product the market is segmented as, Aerosol, Dry Powder Formulation, Spray, Application, Respiratory Diseases, Non-Respiratory Disease
  • Based on Regional the market is segmented as, North America, U.S, Canada, Europe, Germany, U.K., France, Italy, Spain, Asia Pacific, Japan, China, India, South Korea, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, Saudi Arabia, South Africa, UAE, KEY MARKET PLAYERS, AstraZeneca, Sanofi, Vectura, Mylan, GlaxoSmithKline, Mundipharma, Boehringer Ingelheim International GmbH

Regional Analysis:

Inhalable Drugs Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Inhalable Drugs Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

Inhalable Drugs Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Inhalable Drugs Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Inhalable Drugs Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Inhalable Drugs Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Inhalable Drugs Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • nsights
  • The global inhalable drugs market size was valued at USD 25.0 billion in 2018 and is estimated to exhibit a CAGR of 6.3%during the forecast period. Increasing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis is anticipated to boost the market growth. According to the Centers for Disease Control and Prevention (CDC), more than 25 million people were suffering from asthma in the U.S. in 2017, which amounts to approximately 7.7% of the adult population and 8.4% of children.
  • Increasing prevalence of non-respiratory diseases such as diabetes and Parkinson’s disease is a key factor expected to fuel the market for inhalable drugs. Parkinson’s disease is widely reported in people aged 60 years and above. The prevalence rate of this disease increases with age. According to WHO, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population. For instance, in December 2018, INBRIJA, a prescription medicine containing levodopa, was approved by the USFDA for adults.
  • Advancements in inhalable drugs are expected to propel market growth. Advanced inhalation therapy involves the use of surfactant carriers, nanocrystals, and micro and nanoparticles. Therefore, researches are conducted on small molecules to develop innovative inhalable drugs. These advancements in inhalation therapies offer increased systemic availability of drugs, convenience over invasive methods, improved drug interactions, and minimal toxicities. Reformulation of existing non-inhaled molecules into inhaled molecules for enhanced delivery of the drug is providing new growth opportunities to market players. For instance, reformulation of dihydroergotamine (intravenous drug) into mesylate salt breath-actuated MDI device (Tempo) for treatment of migraine.
  • The strong presence of leading players in the field will continue to benefit the global market. These companies focus on unmet market needs, geographic expansion objectives, developing innovative products, and mergers and acquisitions to capitalize their market share. These companies also provide services to various entities in order to improve the quality of drug delivery systems and patient compliance. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of inhalable drugs. Furthermore, these players focus on personnel training and R&D investments to capture a larger share in the market.
  • Product Insights
  • The market has been segmented on the basis of product into aerosols, dry powder formulation, and spray. Dry powder formulation dominated the inhalable drugs market in 2018 owing to higher efficacy and better results in comparison with other forms. Furthermore, the presence of a wide range of products and a strong pipeline for this formulation are factors responsible for its dominant market share.
  • The focus of manufacturers on developing small-sized particle products has increased, which is expected to fuel the market growth during the forecast period. For instance, in April 2019, Cipla launched Niveoli-the first extra-fine particle inhaler developed in India. The inhaler comprises beclomethasone-formoterol and hydrofluoroalkane (HFA), which ensures targeted delivery to small airways in asthma and COPD patients.
  • Aerosols are expected to witness steady growth over the forecast period owing to their user-friendliness. Players are constantly looking to manufacture inhalable products that are easy to use and effective without being too complicated. For instance, in February 2018, Teva Pharmaceuticals launched the QVAR RediHaler inhalation aerosol in the U.S. as a tool for the management of asthma.
  • Application Insights
  • Inhalable drugs are widely used for the treatment of chronic respiratory diseases such as asthma, COPD, bronchospasm, as well as non-respiratory diseases such as diabetes and Parkinson’s disease. Combination therapy of Inhaled Corticosteroid (ICS), Long-Acting Muscarinic Antagonist (LAMA), and Long-Acting β2 Adrenoceptor Agonist (LABA) are extensively used for the treatment of COPDs and asthma due to its effectiveness, ability to reduce inflammation of lungs, and less need for hospitalization.
  • This has driven many manufacturers to develop combination therapies. For instance, in September 2017, the U.S. FDA approved a combination therapy called Trelegy Ellipta for the treatment of COPDs, chronic bronchitis, and emphysema. This medicine consists of three active molecules-fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA).
  • Due to the rising prevalence of diabetes and the high cost of medications, manufacturers have come up with an inhaler as an alternative therapy with reduced cost. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for patients with diabetes. The company started a direct purchase program for inhalable insulin Afrezza for as little as USD 4 per day.
  • Regional Insights
  • Geographically, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the overall market in terms of revenue in 2018, followed by Europe. Both the markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. For instance, in November 2016, Mylan organized the COPD Awareness Month to raise awareness about various treatments (inhaled and other bronchodilators) and their different dosage forms.
  • The Asia Pacific market for inhalable drugs is anticipated to be the fastest-growing segment over the forecast period. This can be attributed to factors such as improving healthcare infrastructure, rising patient awareness, and increasing disposable income. Moreover, new market entrants lead to strong competition, which is expected to play an important role in providing a growth platform to this regional market over the next few years. Growing medical tourism in several Asian countries is also attracting the attention of leading global players to set up in numerous emerging economies with significant growth potential.
  • Inhalable Drugs Market Share Insights
  • There are a large number of players operating in the global market. These players are involved in launching novel products and undertake strategic initiatives to gain a competitive edge. Apart from this, they are also engaged in strategies such as joint ventures, collaborative development, mergers and acquisitions, product expansions, and developments. For instance, in August 2018, Glenmark Pharmaceuticals entered into a licensing agreement to commercialize Tiotropium Bromide dry powder inhaler to treat COPD in Europe.
  • Companies are focusing on developing inhalable drugs and enhanced versions of already existing molecules. There are more than 220 ongoing projects pertaining to inhalable medicines globally. For instance, Breath Therapeutics’ Boston Program for Bronchiolitis Obliterans Syndrome with Liposomal Cyclosporine A for Inhalation is in Phase III clinical trial, which is likely to be launched during the forecast period.
  • KEY MARKET SEGMENTS
  • By Product
  • Aerosol
  • Dry Powder Formulation
  • Spray
  • Application
  • Respiratory Diseases
  • Non-Respiratory Disease
  • By Regional
  • North America
  • U.S
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • KEY MARKET PLAYERS
  • AstraZeneca
  • Sanofi
  • Vectura
  • Mylan
  • GlaxoSmithKline
  • Mundipharma
  • Boehringer Ingelheim International GmbH
  • Cipla Inc."

SkyQuest's Expertise:

The Inhalable Drugs Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Product - Aerosol, Dry Powder Formulation, Spray, Application, Respiratory Diseases, Non-Respiratory Disease
  • By Regional - North America, U.S, Canada, Europe, Germany, U.K., France, Italy, Spain, Asia Pacific, Japan, China, India, South Korea, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, Saudi Arabia, South Africa, UAE, KEY MARKET PLAYERS, AstraZeneca, Sanofi, Vectura, Mylan, GlaxoSmithKline, Mundipharma, Boehringer Ingelheim International GmbH
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • nsights
  • The global inhalable drugs market size was valued at USD 25.0 billion in 2018 and is estimated to exhibit a CAGR of 6.3%during the forecast period. Increasing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis is anticipated to boost the market growth. According to the Centers for Disease Control and Prevention (CDC), more than 25 million people were suffering from asthma in the U.S. in 2017, which amounts to approximately 7.7% of the adult population and 8.4% of children.
  • Increasing prevalence of non-respiratory diseases such as diabetes and Parkinson’s disease is a key factor expected to fuel the market for inhalable drugs. Parkinson’s disease is widely reported in people aged 60 years and above. The prevalence rate of this disease increases with age. According to WHO, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population. For instance, in December 2018, INBRIJA, a prescription medicine containing levodopa, was approved by the USFDA for adults.
  • Advancements in inhalable drugs are expected to propel market growth. Advanced inhalation therapy involves the use of surfactant carriers, nanocrystals, and micro and nanoparticles. Therefore, researches are conducted on small molecules to develop innovative inhalable drugs. These advancements in inhalation therapies offer increased systemic availability of drugs, convenience over invasive methods, improved drug interactions, and minimal toxicities. Reformulation of existing non-inhaled molecules into inhaled molecules for enhanced delivery of the drug is providing new growth opportunities to market players. For instance, reformulation of dihydroergotamine (intravenous drug) into mesylate salt breath-actuated MDI device (Tempo) for treatment of migraine.
  • The strong presence of leading players in the field will continue to benefit the global market. These companies focus on unmet market needs, geographic expansion objectives, developing innovative products, and mergers and acquisitions to capitalize their market share. These companies also provide services to various entities in order to improve the quality of drug delivery systems and patient compliance. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of inhalable drugs. Furthermore, these players focus on personnel training and R&D investments to capture a larger share in the market.
  • Product Insights
  • The market has been segmented on the basis of product into aerosols, dry powder formulation, and spray. Dry powder formulation dominated the inhalable drugs market in 2018 owing to higher efficacy and better results in comparison with other forms. Furthermore, the presence of a wide range of products and a strong pipeline for this formulation are factors responsible for its dominant market share.
  • The focus of manufacturers on developing small-sized particle products has increased, which is expected to fuel the market growth during the forecast period. For instance, in April 2019, Cipla launched Niveoli-the first extra-fine particle inhaler developed in India. The inhaler comprises beclomethasone-formoterol and hydrofluoroalkane (HFA), which ensures targeted delivery to small airways in asthma and COPD patients.
  • Aerosols are expected to witness steady growth over the forecast period owing to their user-friendliness. Players are constantly looking to manufacture inhalable products that are easy to use and effective without being too complicated. For instance, in February 2018, Teva Pharmaceuticals launched the QVAR RediHaler inhalation aerosol in the U.S. as a tool for the management of asthma.
  • Application Insights
  • Inhalable drugs are widely used for the treatment of chronic respiratory diseases such as asthma, COPD, bronchospasm, as well as non-respiratory diseases such as diabetes and Parkinson’s disease. Combination therapy of Inhaled Corticosteroid (ICS), Long-Acting Muscarinic Antagonist (LAMA), and Long-Acting β2 Adrenoceptor Agonist (LABA) are extensively used for the treatment of COPDs and asthma due to its effectiveness, ability to reduce inflammation of lungs, and less need for hospitalization.
  • This has driven many manufacturers to develop combination therapies. For instance, in September 2017, the U.S. FDA approved a combination therapy called Trelegy Ellipta for the treatment of COPDs, chronic bronchitis, and emphysema. This medicine consists of three active molecules-fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA).
  • Due to the rising prevalence of diabetes and the high cost of medications, manufacturers have come up with an inhaler as an alternative therapy with reduced cost. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for patients with diabetes. The company started a direct purchase program for inhalable insulin Afrezza for as little as USD 4 per day.
  • Regional Insights
  • Geographically, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the overall market in terms of revenue in 2018, followed by Europe. Both the markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. For instance, in November 2016, Mylan organized the COPD Awareness Month to raise awareness about various treatments (inhaled and other bronchodilators) and their different dosage forms.
  • The Asia Pacific market for inhalable drugs is anticipated to be the fastest-growing segment over the forecast period. This can be attributed to factors such as improving healthcare infrastructure, rising patient awareness, and increasing disposable income. Moreover, new market entrants lead to strong competition, which is expected to play an important role in providing a growth platform to this regional market over the next few years. Growing medical tourism in several Asian countries is also attracting the attention of leading global players to set up in numerous emerging economies with significant growth potential.
  • Inhalable Drugs Market Share Insights
  • There are a large number of players operating in the global market. These players are involved in launching novel products and undertake strategic initiatives to gain a competitive edge. Apart from this, they are also engaged in strategies such as joint ventures, collaborative development, mergers and acquisitions, product expansions, and developments. For instance, in August 2018, Glenmark Pharmaceuticals entered into a licensing agreement to commercialize Tiotropium Bromide dry powder inhaler to treat COPD in Europe.
  • Companies are focusing on developing inhalable drugs and enhanced versions of already existing molecules. There are more than 220 ongoing projects pertaining to inhalable medicines globally. For instance, Breath Therapeutics’ Boston Program for Bronchiolitis Obliterans Syndrome with Liposomal Cyclosporine A for Inhalation is in Phase III clinical trial, which is likely to be launched during the forecast period.
  • KEY MARKET SEGMENTS
  • By Product
  • Aerosol
  • Dry Powder Formulation
  • Spray
  • Application
  • Respiratory Diseases
  • Non-Respiratory Disease
  • By Regional
  • North America
  • U.S
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • KEY MARKET PLAYERS
  • AstraZeneca
  • Sanofi
  • Vectura
  • Mylan
  • GlaxoSmithKline
  • Mundipharma
  • Boehringer Ingelheim International GmbH
  • Cipla Inc."
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Inhalable Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Inhalable Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • nsights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The global inhalable drugs market size was valued at USD 25.0 billion in 2018 and is estimated to exhibit a CAGR of 6.3%during the forecast period. Increasing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis is anticipated to boost the market growth. According to the Centers for Disease Control and Prevention (CDC), more than 25 million people were suffering from asthma in the U.S. in 2017, which amounts to approximately 7.7% of the adult population and 8.4% of children.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Increasing prevalence of non-respiratory diseases such as diabetes and Parkinson’s disease is a key factor expected to fuel the market for inhalable drugs. Parkinson’s disease is widely reported in people aged 60 years and above. The prevalence rate of this disease increases with age. According to WHO, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population. For instance, in December 2018, INBRIJA, a prescription medicine containing levodopa, was approved by the USFDA for adults.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Advancements in inhalable drugs are expected to propel market growth. Advanced inhalation therapy involves the use of surfactant carriers, nanocrystals, and micro and nanoparticles. Therefore, researches are conducted on small molecules to develop innovative inhalable drugs. These advancements in inhalation therapies offer increased systemic availability of drugs, convenience over invasive methods, improved drug interactions, and minimal toxicities. Reformulation of existing non-inhaled molecules into inhaled molecules for enhanced delivery of the drug is providing new growth opportunities to market players. For instance, reformulation of dihydroergotamine (intravenous drug) into mesylate salt breath-actuated MDI device (Tempo) for treatment of migraine.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The strong presence of leading players in the field will continue to benefit the global market. These companies focus on unmet market needs, geographic expansion objectives, developing innovative products, and mergers and acquisitions to capitalize their market share. These companies also provide services to various entities in order to improve the quality of drug delivery systems and patient compliance. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of inhalable drugs. Furthermore, these players focus on personnel training and R&D investments to capture a larger share in the market.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Product Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The market has been segmented on the basis of product into aerosols, dry powder formulation, and spray. Dry powder formulation dominated the inhalable drugs market in 2018 owing to higher efficacy and better results in comparison with other forms. Furthermore, the presence of a wide range of products and a strong pipeline for this formulation are factors responsible for its dominant market share.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The focus of manufacturers on developing small-sized particle products has increased, which is expected to fuel the market growth during the forecast period. For instance, in April 2019, Cipla launched Niveoli-the first extra-fine particle inhaler developed in India. The inhaler comprises beclomethasone-formoterol and hydrofluoroalkane (HFA), which ensures targeted delivery to small airways in asthma and COPD patients.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Aerosols are expected to witness steady growth over the forecast period owing to their user-friendliness. Players are constantly looking to manufacture inhalable products that are easy to use and effective without being too complicated. For instance, in February 2018, Teva Pharmaceuticals launched the QVAR RediHaler inhalation aerosol in the U.S. as a tool for the management of asthma.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Inhalable drugs are widely used for the treatment of chronic respiratory diseases such as asthma, COPD, bronchospasm, as well as non-respiratory diseases such as diabetes and Parkinson’s disease. Combination therapy of Inhaled Corticosteroid (ICS), Long-Acting Muscarinic Antagonist (LAMA), and Long-Acting β2 Adrenoceptor Agonist (LABA) are extensively used for the treatment of COPDs and asthma due to its effectiveness, ability to reduce inflammation of lungs, and less need for hospitalization.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • This has driven many manufacturers to develop combination therapies. For instance, in September 2017, the U.S. FDA approved a combination therapy called Trelegy Ellipta for the treatment of COPDs, chronic bronchitis, and emphysema. This medicine consists of three active molecules-fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA).
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Due to the rising prevalence of diabetes and the high cost of medications, manufacturers have come up with an inhaler as an alternative therapy with reduced cost. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for patients with diabetes. The company started a direct purchase program for inhalable insulin Afrezza for as little as USD 4 per day.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Regional Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Geographically, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the overall market in terms of revenue in 2018, followed by Europe. Both the markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. For instance, in November 2016, Mylan organized the COPD Awareness Month to raise awareness about various treatments (inhaled and other bronchodilators) and their different dosage forms.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The Asia Pacific market for inhalable drugs is anticipated to be the fastest-growing segment over the forecast period. This can be attributed to factors such as improving healthcare infrastructure, rising patient awareness, and increasing disposable income. Moreover, new market entrants lead to strong competition, which is expected to play an important role in providing a growth platform to this regional market over the next few years. Growing medical tourism in several Asian countries is also attracting the attention of leading global players to set up in numerous emerging economies with significant growth potential.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Inhalable Drugs Market Share Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • There are a large number of players operating in the global market. These players are involved in launching novel products and undertake strategic initiatives to gain a competitive edge. Apart from this, they are also engaged in strategies such as joint ventures, collaborative development, mergers and acquisitions, product expansions, and developments. For instance, in August 2018, Glenmark Pharmaceuticals entered into a licensing agreement to commercialize Tiotropium Bromide dry powder inhaler to treat COPD in Europe.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Companies are focusing on developing inhalable drugs and enhanced versions of already existing molecules. There are more than 220 ongoing projects pertaining to inhalable medicines globally. For instance, Breath Therapeutics’ Boston Program for Bronchiolitis Obliterans Syndrome with Liposomal Cyclosporine A for Inhalation is in Phase III clinical trial, which is likely to be launched during the forecast period.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Product
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Aerosol
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Dry Powder Formulation
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Spray
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Respiratory Diseases
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Non-Respiratory Disease
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Regional
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • U.S
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Canada
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Germany
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • U.K.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • France
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Italy
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Spain
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Japan
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • China
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • India
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • South Korea
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Brazil
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Mexico
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Argentina
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Middle East & Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Saudi Arabia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • South Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • UAE
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET PLAYERS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • AstraZeneca
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Sanofi
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Vectura
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Mylan
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • GlaxoSmithKline
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Mundipharma
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Boehringer Ingelheim International GmbH
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cipla Inc."
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the Inhalable Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Inhalable Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Inhalable Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Inhalable Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

The market for Inhalable Drugs was estimated to be valued at US$ XX Mn in 2021.

The Inhalable Drugs Market is estimated to grow at a CAGR of XX% by 2028.

The Inhalable Drugs Market is segmented on the basis of Product, Regional.

Based on region, the Inhalable Drugs Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Inhalable Drugs Market are nsights , The inhalable drugs market size was valued at USD 25.0 billion in 2018 and is estimated to exhibit a CAGR of 6.3%during the forecast period. Increasing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis is anticipated to boost the market growth. According to the Centers for Disease Control and Prevention (CDC), more than 25 million people were suffering from asthma in the U.S. in 2017, which amounts to approximately 7.7% of the adult population and 8.4% of children. , Increasing prevalence of non-respiratory diseases such as diabetes and Parkinson’s disease is a key factor expected to fuel the market for inhalable drugs. Parkinson’s disease is widely reported in people aged 60 years and above. The prevalence rate of this disease increases with age. According to WHO, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population. For instance, in December 2018, INBRIJA, a prescription medicine containing levodopa, was approved by the USFDA for adults. , Advancements in inhalable drugs are expected to propel market growth. Advanced inhalation therapy involves the use of surfactant carriers, nanocrystals, and micro and nanoparticles. Therefore, researches are conducted on small molecules to develop innovative inhalable drugs. These advancements in inhalation therapies offer increased systemic availability of drugs, convenience over invasive methods, improved drug interactions, and minimal toxicities. Reformulation of existing non-inhaled molecules into inhaled molecules for enhanced delivery of the drug is providing new growth opportunities to market players. For instance, reformulation of dihydroergotamine (intravenous drug) into mesylate salt breath-actuated MDI device (Tempo) for treatment of migraine. , The strong presence of leading players in the field will continue to benefit the market. These companies focus on unmet market needs, geographic expansion objectives, developing innovative products, and mergers and acquisitions to capitalize their market share. These companies also provide services to various entities in order to improve the quality of drug delivery systems and patient compliance. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of inhalable drugs. Furthermore, these players focus on personnel training and R&D investments to capture a larger share in the market. , Product Insights , The market has been segmented on the basis of product into aerosols, dry powder formulation, and spray. Dry powder formulation dominated the inhalable drugs market in 2018 owing to higher efficacy and better results in comparison with other forms. Furthermore, the presence of a wide range of products and a strong pipeline for this formulation are factors responsible for its dominant market share. , The focus of manufacturers on developing small-sized particle products has increased, which is expected to fuel the market growth during the forecast period. For instance, in April 2019, Cipla launched Niveoli-the first extra-fine particle inhaler developed in India. The inhaler comprises beclomethasone-formoterol and hydrofluoroalkane (HFA), which ensures targeted delivery to small airways in asthma and COPD patients. , Aerosols are expected to witness steady growth over the forecast period owing to their user-friendliness. Players are constantly looking to manufacture inhalable products that are easy to use and effective without being too complicated. For instance, in February 2018, Teva Pharmaceuticals launched the QVAR RediHaler inhalation aerosol in the U.S. as a tool for the management of asthma. , Application Insights , Inhalable drugs are widely used for the treatment of chronic respiratory diseases such as asthma, COPD, bronchospasm, as well as non-respiratory diseases such as diabetes and Parkinson’s disease. Combination therapy of Inhaled Corticosteroid (ICS), Long-Acting Muscarinic Antagonist (LAMA), and Long-Acting β2 Adrenoceptor Agonist (LABA) are extensively used for the treatment of COPDs and asthma due to its effectiveness, ability to reduce inflammation of lungs, and less need for hospitalization. , This has driven many manufacturers to develop combination therapies. For instance, in September 2017, the U.S. FDA approved a combination therapy called Trelegy Ellipta for the treatment of COPDs, chronic bronchitis, and emphysema. This medicine consists of three active molecules-fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA). , Due to the rising prevalence of diabetes and the high cost of medications, manufacturers have come up with an inhaler as an alternative therapy with reduced cost. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for patients with diabetes. The company started a direct purchase program for inhalable insulin Afrezza for as little as USD 4 per day. , Regional Insights , Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the overall market in terms of revenue in 2018, followed by Europe. Both the markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. For instance, in November 2016, Mylan organized the COPD Awareness Month to raise awareness about various treatments (inhaled and other bronchodilators) and their different dosage forms. , The Asia Pacific market for inhalable drugs is anticipated to be the fastest-growing segment over the forecast period. This can be attributed to factors such as improving healthcare infrastructure, rising patient awareness, and increasing disposable income. Moreover, new market entrants lead to strong competition, which is expected to play an important role in providing a growth platform to this regional market over the next few years. Growing medical tourism in several Asian countries is also attracting the attention of leading players to set up in numerous emerging economies with significant growth potential. , Inhalable Drugs Market Share Insights , There are a large number of players operating in the market. These players are involved in launching novel products and undertake strategic initiatives to gain a competitive edge. Apart from this, they are also engaged in strategies such as joint ventures, collaborative development, mergers and acquisitions, product expansions, and developments. For instance, in August 2018, Glenmark Pharmaceuticals entered into a licensing agreement to commercialize Tiotropium Bromide dry powder inhaler to treat COPD in Europe. , Companies are focusing on developing inhalable drugs and enhanced versions of already existing molecules. There are more than 220 ongoing projects pertaining to inhalable medicines globally. For instance, Breath Therapeutics’ Boston Program for Bronchiolitis Obliterans Syndrome with Liposomal Cyclosporine A for Inhalation is in Phase III clinical trial, which is likely to be launched during the forecast period. , KEY MARKET SEGMENTS, By Product, Aerosol , Dry Powder Formulation , Spray , Application , Respiratory Diseases , Non-Respiratory Disease , By Regional , North America , U.S , Canada , Europe , Germany , U.K. , France , Italy , Spain , Asia Pacific , Japan , China , India , South Korea , Latin America , Brazil , Mexico , Argentina , Middle East & Africa , Saudi Arabia , South Africa , UAE , KEY MARKET PLAYERS, AstraZeneca , Sanofi , Vectura , Mylan , GlaxoSmithKline , Mundipharma , Boehringer Ingelheim International GmbH , Cipla Inc.".

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Psychedelic Drugs Market
Buy Now GET FREE SAMPLE
Prescription Drugs Market
Buy Now GET FREE SAMPLE
Over The Counter Drugs Market
Buy Now GET FREE SAMPLE
Smart Inhalers Market
Buy Now GET FREE SAMPLE
Lyophilized Injectable Drugs Market
Buy Now GET FREE SAMPLE
Schizophrenia Drugs Market
Buy Now GET FREE SAMPLE
Pharmaceuticals Market
Buy Now GET FREE SAMPLE
Drug Delivery Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Inhalable Drugs Market

Report ID: UCMIG35I2239

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE